# Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

> **NCT00656474** · PHASE1,PHASE2 · COMPLETED · sponsor: **TR Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Wounds

## Interventions

- **DRUG:** Placebo gel
- **DRUG:** GLYC-101 gel (1.0 %)

## Key facts

- **NCT ID:** NCT00656474
- **Lead sponsor:** TR Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-04
- **Final completion:** 2008-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656474, "Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00656474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*